References
- Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351(9103):659–64.
- Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74(5):799–805.
- Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med. 1974;81(6):792–4.
- Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–53.
- Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43(3):387–91.
- Migita K, Agematsu K, Yazaki M, Nonaka F, Nakamura A, Toma T, et al. Familial Mediterranean fever: genotype-phenotype correlations in Japanese patients. Medicine (Baltimore). 2014;93(3):158–64.
- Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–51.
- Kishida D, Nakamura A, Yazaki M, Tsuchiya-Suzuki A, Matsuda M, Ikeda S. Genotype-phenotype correlation in Japanese patients with familial Mediterranean fever: differences in genotype and clinical features between Japanese and Mediterranean populations. Arthritis Res Ther. 2014;16(5):439.
- Koka S, Petro TM, Reinhardt RA. Estrogen inhibits interleukin-1beta-induced interleukin-6 production by human osteoblast-like cells. J Interferon Cytokine Res. 1998;18(7):479–83.
- Satis H, Armagan B, Bodakci E, Atas N, Sari A, Yasar Bilge NS, et al. Colchicine Intolerance in FMF Patients and Primary Obstacles for Optimal Dosing. Turk J Med Sci. 2020. doi:10.3906/sag-2001-261. [Online ahead of print].